{"id":67677,"date":"2025-02-05T16:54:34","date_gmt":"2025-02-05T05:54:34","guid":{"rendered":"https:\/\/hudson.org.au?post_type=hdsn_news_post&p=67677"},"modified":"2025-04-03T17:38:57","modified_gmt":"2025-04-03T06:38:57","slug":"breakthrough-ibd-treatment-heads-into-clinical-trials","status":"publish","type":"hdsn_news_post","link":"https:\/\/hudson.org.au\/news\/breakthrough-ibd-treatment-heads-into-clinical-trials\/","title":{"rendered":"Breakthrough IBD treatment heads into clinical trials"},"content":{"rendered":"\n

People living with inflammatory bowel disease (IBD)<\/a> have new hope, with clinical trials beginning for a breakthrough treatment for one of the most difficult to treat conditions associated with the disease.<\/p>\n\n\n\n

IBD is the collective term for Crohn\u2019s disease and Ulcerative Colitis \u2013 both inflammatory conditions of the digestive tract, often affecting the bowel.<\/p>\n\n\n\n

Complex fistulising perianal Crohn\u2019s disease is a debilitating and incurable form in which abnormal connections form between the lumen of the bowel and other sections of bowel, vagina, uterus and skin, causing faecal incontinence, recurrent severe infections, chronic inflammation and tissue damage.<\/p>\n\n\n\n

Until now this condition has been largely incurable.<\/p>\n\n\n\n

IBD treatment reaches clinical trial stage<\/h2>\n\n\n\n

Current therapies are expensive, unreliable and have significant side effects. Stem cells are being investigated for use in this condition, but these experimental therapies are highly expensive and difficult to manufacture. However, an upcoming new treatment candidate promises excellent results at a significantly lower cost than current options.<\/p>\n\n\n\n

The treatment, pioneered by Associate Professor Rebecca Lim<\/a> and her team at Hudson Institute of Medical Research, uses extracellular vesicles (EVs) derived from human amniotic epithelial cells (hAECs), to deliver the same benefits as stem cell treatments at a greatly reduced cost.<\/p>\n\n\n\n

Now, in collaboration with Monash Health and Monash University, this candidate is set to undergo its first clinical trial.<\/p>\n\n\n\n

The trial will be led by Dr Charlotte Keung<\/a>, an IBD specialist gastroenterologist at Monash Health and early career researcher at Monash University, and member of the Amnion Cell Biology Research group<\/a> at Hudson Institute.<\/p>\n\n\n\n

She believes EVs have characteristics that give them therapeutic advantages over traditional stem cell-based therapies.<\/p>\n\n\n\n

\u201cThe goal is to increase treatment accessibility for a debilitating condition without other options, by developing a therapy with significant manufacturing cost reductions and improved commercialisation potential,\u201d she said.<\/p>\n\n\n\n

\u201chAEC-EV therapy reduces the significant manufacturing, cold chain logistics, clinical administration and cost limitations associated with live cell treatment.\u201d<\/p>\n\n\n\n

Treatment candidate targets one-third of Crohn’s disease patients<\/h2>\n\n\n\n

According to Global Data Crohn\u2019s Disease has a current total market size of $9.2 billion expected to grow to $13.4 billion by 2026. One third of Crohn\u2019s patients will develop fistulas.<\/p>\n\n\n\n

This will be a first-in-human use of EV therapy for Crohn\u2019s disease worldwide and the 2nd human EV trial in Australia. hAEC-EVs will be administered via local injection to 15 participants with complex refractory Crohn\u2019s perianal fistulas.<\/p>\n\n\n\n

According to Hudson Institute\u2019s CEO and Director, Professor Elizabeth Hartland AM<\/a>, the primary aim of the trial is assessing the safety of the therapy. The secondary aim is to investigate whether the candidate is effective in healing perianal fistulae and improving patient quality of life. These aims will help researchers to further optimise the therapy.<\/p>\n\n\n\n

This exciting new regenerative therapy trial has opened recruitment for a first-in-human clinical trial. All clinical procedures will be conducted at appropriate Monash Health facilities.<\/p>\n\n\n\n

It will be overseen by internationally recognised clinician-scientist Associate Professor Greg Moore, who established and heads a large multidisciplinary IBD Unit at Monash Health. He is active in basic and translational research, clinical trials, education and clinical medicine, with a proven record in research infrastructure development. He is a Director on the board of Crohn\u2019s and Colitis Australia.<\/p>\n\n\n\n

Exosome BioSciences P\/L<\/h2>\n\n\n
\n
\"Exosome<\/figure>\n<\/div>\n\n\n

Exosome BioSciences P\/L <\/strong>is driving the trial, confident that its novel hAEC exosome platform is highly effective in pre-clinical models over a range of conditions including bronchopulmonary dysplasia<\/a>, asthma and stroke, as well as pulmonary, liver and kidney fibrosis.<\/p>\n\n\n\n

Exosome BioSciences Pty Ltd is a spin-off company established in 2023 to commercialise a portfolio of Intellectual Property (IP) developed by Hudson Institute of Medical Research, Monash University and Monash Health. The company has an exclusive license for the relevant IP including Patent applications, trade secrets and proprietary materials.<\/p>\n\n\n\n

In 2023 Exosome BioSciences was awarded a $1.5 million grant from CUREator to develop novel exosome therapies to fund this clinical trial. CUREator is an Australian biotech incubator delivered by Brandon BioCatalyst with funding from the Australian Federal Government\u2019s Medical Research Future Fund.<\/p>\n\n\n\n

What are extracellular vesicles?<\/h2>\n\n\n\n

EVs are small, membrane-bound particles released by almost all cell types. They play a crucial role in intercellular communication by transporting proteins, lipids, and nucleic acids between cells.<\/p>\n\n\n\n

Depending on the cell of origin, EVs can play a role in:<\/p>\n\n\n\n